Roche CEO Says US 301 Probe Could Reshape Drug Pricing Talks

Roche Holding AG Chief Executive Officer Thomas Schinecker signaled that a new investigation into drug costs conducted by the Trump administration might pressure countries to review their own drug prices.

“The US will launch 301 investigations against US trading partners that people should allocate a certain percentage of GDP into innovation of health care and medicines,” he said on a conference call Thursday. “In all conversations with governments around the world, we do have conversations on what this all means, also for these governments. Because I think it’s important to raise awareness.”

The probe, under Section 301 of the Trade ...